Inhibition of cell growth and nuclear factor-κB activity in pancreatic cancer cell lines by a tylophorine analogue, DCB-3503

Her Shyong Shiah, Wenli Gao, David C. Baker, Yung Chi Cheng

Research output: Contribution to journalArticle

40 Citations (Scopus)

Abstract

A tylophorine analogue, DCB-3503, has been shown to have potent activity against tumor growth in vitro and in vivo, as well as activity in an autoimmune disease model in vivo. This study focuses on investigating the mechanisms responsible for antitumor activity of DCB-3503. The concentrations for inhibiting 50% growth/colony formation ability are 50/ 162 and 40/149 nmol/L for PANC-1 and HPAC cells, respectively. The growth inhibition effects are associated with DCB-3503-induced reprogramming of tumor cells. DCB-3503 could interfere w: th cell cycle progression. Several cell cycle regulatory proteins, including cyclin D1, are down-regulated by DCB-3503. Using several different transcription elements coupled with a reporter gene, it was found that the nuclear factor-κB (NF-κB) signaling pathway is the most sensitive pathway mediator affected by DCB-3503. The inhibition of NF-κB activity is dependent on the down-regulation of nuclear phosphorylated p65, a component of the active form of the NF-κB complex. Such a decrease in nuclear phosphorylated p65 can be reversed by a proteosome inhibitor. Furthermore, the activity and protein expression of nuclear IκB kinase α, which is responsible for p65 phosphorylation, is suppressed and down-regulated in cells treated with DCB-3503. In summary, DCB-3503 could affect cell cycle regulatory proteins and is a potent modulator of NF-κB function. It is a potentially useful compound in the management of cancers in which cyclin D1 overexpression and high NF-κB activity play a pivotal role.

Original languageEnglish
Pages (from-to)2484-2493
Number of pages10
JournalMolecular Cancer Therapeutics
Volume5
Issue number10
DOIs
Publication statusPublished - Oct 1 2006
Externally publishedYes

Fingerprint

Pancreatic Neoplasms
Intercellular Signaling Peptides and Proteins
Cell Line
Cell Cycle Proteins
Cyclin D1
Growth
Neoplasms
tylophorine
DCB 3503
Nuclear Proteins
Reporter Genes
Autoimmune Diseases
Cell Cycle
Phosphotransferases
Down-Regulation
Phosphorylation

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Inhibition of cell growth and nuclear factor-κB activity in pancreatic cancer cell lines by a tylophorine analogue, DCB-3503. / Shiah, Her Shyong; Gao, Wenli; Baker, David C.; Cheng, Yung Chi.

In: Molecular Cancer Therapeutics, Vol. 5, No. 10, 01.10.2006, p. 2484-2493.

Research output: Contribution to journalArticle

@article{af18d133ffbe4803a18beb2f6375e201,
title = "Inhibition of cell growth and nuclear factor-κB activity in pancreatic cancer cell lines by a tylophorine analogue, DCB-3503",
abstract = "A tylophorine analogue, DCB-3503, has been shown to have potent activity against tumor growth in vitro and in vivo, as well as activity in an autoimmune disease model in vivo. This study focuses on investigating the mechanisms responsible for antitumor activity of DCB-3503. The concentrations for inhibiting 50{\%} growth/colony formation ability are 50/ 162 and 40/149 nmol/L for PANC-1 and HPAC cells, respectively. The growth inhibition effects are associated with DCB-3503-induced reprogramming of tumor cells. DCB-3503 could interfere w: th cell cycle progression. Several cell cycle regulatory proteins, including cyclin D1, are down-regulated by DCB-3503. Using several different transcription elements coupled with a reporter gene, it was found that the nuclear factor-κB (NF-κB) signaling pathway is the most sensitive pathway mediator affected by DCB-3503. The inhibition of NF-κB activity is dependent on the down-regulation of nuclear phosphorylated p65, a component of the active form of the NF-κB complex. Such a decrease in nuclear phosphorylated p65 can be reversed by a proteosome inhibitor. Furthermore, the activity and protein expression of nuclear IκB kinase α, which is responsible for p65 phosphorylation, is suppressed and down-regulated in cells treated with DCB-3503. In summary, DCB-3503 could affect cell cycle regulatory proteins and is a potent modulator of NF-κB function. It is a potentially useful compound in the management of cancers in which cyclin D1 overexpression and high NF-κB activity play a pivotal role.",
author = "Shiah, {Her Shyong} and Wenli Gao and Baker, {David C.} and Cheng, {Yung Chi}",
year = "2006",
month = "10",
day = "1",
doi = "10.1158/1535-7163.MCT-06-0146",
language = "English",
volume = "5",
pages = "2484--2493",
journal = "Molecular Cancer Therapeutics",
issn = "1535-7163",
publisher = "American Association for Cancer Research Inc.",
number = "10",

}

TY - JOUR

T1 - Inhibition of cell growth and nuclear factor-κB activity in pancreatic cancer cell lines by a tylophorine analogue, DCB-3503

AU - Shiah, Her Shyong

AU - Gao, Wenli

AU - Baker, David C.

AU - Cheng, Yung Chi

PY - 2006/10/1

Y1 - 2006/10/1

N2 - A tylophorine analogue, DCB-3503, has been shown to have potent activity against tumor growth in vitro and in vivo, as well as activity in an autoimmune disease model in vivo. This study focuses on investigating the mechanisms responsible for antitumor activity of DCB-3503. The concentrations for inhibiting 50% growth/colony formation ability are 50/ 162 and 40/149 nmol/L for PANC-1 and HPAC cells, respectively. The growth inhibition effects are associated with DCB-3503-induced reprogramming of tumor cells. DCB-3503 could interfere w: th cell cycle progression. Several cell cycle regulatory proteins, including cyclin D1, are down-regulated by DCB-3503. Using several different transcription elements coupled with a reporter gene, it was found that the nuclear factor-κB (NF-κB) signaling pathway is the most sensitive pathway mediator affected by DCB-3503. The inhibition of NF-κB activity is dependent on the down-regulation of nuclear phosphorylated p65, a component of the active form of the NF-κB complex. Such a decrease in nuclear phosphorylated p65 can be reversed by a proteosome inhibitor. Furthermore, the activity and protein expression of nuclear IκB kinase α, which is responsible for p65 phosphorylation, is suppressed and down-regulated in cells treated with DCB-3503. In summary, DCB-3503 could affect cell cycle regulatory proteins and is a potent modulator of NF-κB function. It is a potentially useful compound in the management of cancers in which cyclin D1 overexpression and high NF-κB activity play a pivotal role.

AB - A tylophorine analogue, DCB-3503, has been shown to have potent activity against tumor growth in vitro and in vivo, as well as activity in an autoimmune disease model in vivo. This study focuses on investigating the mechanisms responsible for antitumor activity of DCB-3503. The concentrations for inhibiting 50% growth/colony formation ability are 50/ 162 and 40/149 nmol/L for PANC-1 and HPAC cells, respectively. The growth inhibition effects are associated with DCB-3503-induced reprogramming of tumor cells. DCB-3503 could interfere w: th cell cycle progression. Several cell cycle regulatory proteins, including cyclin D1, are down-regulated by DCB-3503. Using several different transcription elements coupled with a reporter gene, it was found that the nuclear factor-κB (NF-κB) signaling pathway is the most sensitive pathway mediator affected by DCB-3503. The inhibition of NF-κB activity is dependent on the down-regulation of nuclear phosphorylated p65, a component of the active form of the NF-κB complex. Such a decrease in nuclear phosphorylated p65 can be reversed by a proteosome inhibitor. Furthermore, the activity and protein expression of nuclear IκB kinase α, which is responsible for p65 phosphorylation, is suppressed and down-regulated in cells treated with DCB-3503. In summary, DCB-3503 could affect cell cycle regulatory proteins and is a potent modulator of NF-κB function. It is a potentially useful compound in the management of cancers in which cyclin D1 overexpression and high NF-κB activity play a pivotal role.

UR - http://www.scopus.com/inward/record.url?scp=33750457941&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33750457941&partnerID=8YFLogxK

U2 - 10.1158/1535-7163.MCT-06-0146

DO - 10.1158/1535-7163.MCT-06-0146

M3 - Article

VL - 5

SP - 2484

EP - 2493

JO - Molecular Cancer Therapeutics

JF - Molecular Cancer Therapeutics

SN - 1535-7163

IS - 10

ER -